These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 19541663

  • 21. Dual renin-angiotensin system blockade and kidney disease.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA.
    J Am Coll Cardiol; 2009 Jul 14; 54(3):278-9; author reply 279-80. PubMed ID: 19589445
    [No Abstract] [Full Text] [Related]

  • 22. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Katavetin P, Katavetin P.
    N Engl J Med; 2009 Oct 01; 361(14):1410-1; author reply 1411. PubMed ID: 19802919
    [No Abstract] [Full Text] [Related]

  • 23. Moving beyond angiotensin II to also target aldosterone?
    Little WC, Kirkman PM.
    J Am Coll Cardiol; 2009 Aug 04; 54(6):513-4. PubMed ID: 19643311
    [No Abstract] [Full Text] [Related]

  • 24. Angiotensin converting enzyme inhibitor does not reduce proteinuria in an infant with congenital nephrotic syndrome of the Finnish type.
    Birnbacher R, Förster E, Aufricht C.
    Pediatr Nephrol; 1995 Jun 04; 9(3):400. PubMed ID: 7632545
    [No Abstract] [Full Text] [Related]

  • 25. RAAS inhibition/blockade in patients with cardiovascular disease: implications of recent large-scale randomised trials for clinical practice.
    Pitt B.
    Heart; 2009 Aug 04; 95(15):1205-8. PubMed ID: 19401281
    [No Abstract] [Full Text] [Related]

  • 26. Angiotensin receptor blockers: current status and future prospects.
    Kumar S, Ram CV.
    Indian Heart J; 2007 Aug 04; 59(6):443-53. PubMed ID: 19151457
    [No Abstract] [Full Text] [Related]

  • 27. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 28. Aliskiren combined with losartan in diabetes and nephropathy.
    Anderson S, Komers R.
    N Engl J Med; 2008 Sep 04; 359(10):1069; author reply 1069-70. PubMed ID: 18777613
    [No Abstract] [Full Text] [Related]

  • 29. [Hypertension 2007-2008].
    Chatzikyrkou C, Menne J, Haller H.
    Med Klin (Munich); 2009 Aug 04; 104(8):614-21. PubMed ID: 19701732
    [Abstract] [Full Text] [Related]

  • 30. Successful treatment of a patient with nephrotic syndrome associated with chronic lymphocytic leukemia.
    Takahashi F, Ogawa Y, Hasebe N, Natori S, Tokusashi Y, Miyokawa N, Kikuchi K.
    Intern Med; 2000 Mar 04; 39(3):256-9. PubMed ID: 10772132
    [Abstract] [Full Text] [Related]

  • 31. [The renin-angiotensin system].
    Hilgers KF.
    Urologe A; 2009 Aug 04; 48(8):925-33; quiz 934-5. PubMed ID: 19669119
    [No Abstract] [Full Text] [Related]

  • 32. Congenital nephrotic syndrome responsive to angiotensin-converting enzyme inhibition.
    Sreedharan R, Bockenhauer D.
    Pediatr Nephrol; 2005 Sep 04; 20(9):1340-2. PubMed ID: 15965772
    [Abstract] [Full Text] [Related]

  • 33. Management of patients with nephrotic syndrome.
    de Seigneux S, Martin PY.
    Swiss Med Wkly; 2009 Jul 25; 139(29-30):416-22. PubMed ID: 19680831
    [Abstract] [Full Text] [Related]

  • 34. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 25; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 35. Effect of lisinopril on proteinuria in children with nephrotic syndrome in Ilorin, Nigeria.
    Adedoyin OT, Ologe MO, Anigilaje EA, Adeniyi A.
    Pediatr Nephrol; 2003 Jul 25; 18(7):727-8. PubMed ID: 12734747
    [No Abstract] [Full Text] [Related]

  • 36. Steroid-responsive nephrotic syndrome in a patient with nail-patella syndrome.
    Hari P, Mantan M, Dinda A, Hari S, Bagga A.
    Pediatr Nephrol; 2006 Aug 25; 21(8):1197-9. PubMed ID: 16807765
    [Abstract] [Full Text] [Related]

  • 37. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME, Epstein BJ.
    J Cardiovasc Nurs; 2009 Aug 25; 24(5):380-9. PubMed ID: 19707098
    [Abstract] [Full Text] [Related]

  • 38. [Non-antiarrhythmic pharmacological treatment of atrial fibrillation: focus on drugs acting on the renin-angiotensin system].
    Durin O, Pedrinazzi C, Inama G.
    G Ital Cardiol (Rome); 2008 Oct 25; 9(10 Suppl 1):5S-10S. PubMed ID: 19195299
    [Abstract] [Full Text] [Related]

  • 39. [Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].
    Lonati C, Morganti A.
    Pediatr Med Chir; 2009 Oct 25; 31(3):137-9. PubMed ID: 19739495
    [No Abstract] [Full Text] [Related]

  • 40. Angiotensin converting enzyme inhibitor improves nephrotic syndrome associated with cyanotic congenital heart disease.
    Watanabe Y, Fukuzawa Y, Inaguma D.
    Clin Nephrol; 1996 May 25; 45(5):362-3. PubMed ID: 8738675
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.